✦ LIBER ✦

Herceptest: Her2 expression and gene amplification in non-small cell lung cancer

✍ Scribed by G. Cox; M. Vyberg; B. Melgaard; J. Askaa; A. Oster; K.J. O'Byrne

Publisher: John Wiley and Sons
Year: 2001
Tongue: French
Weight: 343 KB
Volume: 92
Category: Article
ISSN: 0020-7136
DOI: 10.1002/ijc.1214

No coin nor oath required. For personal study only.

✦ Synopsis

HER2 is an erbB/HER type 1 tyrosine kinase receptor that is frequently over-expressed in malignant epithelial tumours. Herceptin, a humanised mouse monoclonal antibody to HER2, is proven therapeutically in the management of metastatic breast cancer, significantly prolonging survival when combined with cytotoxic chemotherapeutic agents. Immunohistochemical studies suggest that non-small-cell lung cancer (NSCLC) tumours may over-express HER2. Our aim was to evaluate HER2 gene amplification and semi-quantitative immuno-expression in NSCLC. A total of 344 NSCLC cases were immunostained for HER2 expression in 2 centres using the HercepTest. Fluorescence in situ hybridisation (FISH) analysis for HER2 gene amplification was performed on most positive cases and a subset of negative cases. Fifteen cases (4.3%) demonstrated 2؉ or 3؉ membranous HER2 immunoexpression. There was no correlation between immuno-expression and tumour histology or grade. Tumours from higher-stage disease were more often HercepTest-positive (p < 0.001). All 4 HercepTest 3 ؉ cases demonstrated gene amplification. One of the 5 2؉ cases tested for gene amplification showed areas of borderline amplification and areas of polyploidy. None of the 19 HercepTest-negative cases demonstrated gene amplification or polyploidy (p < 0.001). Gene amplification was demonstrated in all HercepTest 3؉ scoring NSCLC cases. Unlike breast cancer, gene amplification and HER2 protein over-expression assessed by the HercepTest appeared to be uncommon in NSCLC. Herceptin may therefore target only a small proportion of NSCLC tumours and be of limited clinical value in this disease, particularly in the adjuvant setting.

📜 SIMILAR VOLUMES

Identification of TDE2 gene and its expr

Identification of TDE2 gene and its expression in non-small cell lung cancer

✍ Audrey Player; John Gillespie; Takeshi Fujii; Junya Fukuoka; Tatiana Dracheva; D 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 336 KB 👁 2 views

## Abstract __TDE2__, a gene with sequence similarity to the mouse testicular tumor‐differentially‐expressed (__Tde1__/__MUSTETU__) gene, was identified by serial analysis of gene expression (SAGE) in nonsmall cell lung cancers (NSCLC). Here we characterized the __TDE2__ gene and determined its tra

HER 2/neu expression and gene amplificat

HER 2/neu expression and gene amplification in colon cancer

✍ Daniel R. Nathanson; Alfred T. Culliford IV; Jinru Shia; Beiyun Chen; Matthew D' 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 310 KB 👁 1 views

## Abstract HER 2/__neu__ is an important oncogene in breast cancer, but the prevalence and significance of HER 2/__neu__ gene amplification in colon cancer have been poorly documented. We have evaluated HER 2/__neu__ gene amplification and protein overexpression in a series of colon cancers to ass

Chromogranin A gene expression in non-sm

Chromogranin A gene expression in non-small cell lung carcinomas

✍ Abbona, Giancarlo; Papotti, Mauro; Viberti, Laura; Macr??, Luigia; Stella, Anna; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB 👁 2 views

Evidence for the existence of neuroendocrine (NE) differentiation in non-small cell lung carcinomas (NSCLCs) is at present based on histochemical, ultrastructural, and immunohistochemical data. The aim of this study was to investigate the extent of NE differentiation in NSCLCs as revealed by mRNA an

HMGA2 overexpression in non-small cell l

HMGA2 overexpression in non-small cell lung cancer

✍ Britta Meyer; Siegfried Loeschke; Anke Schultze; Thomas Weigel; Martin Sandkamp; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 318 KB 👁 1 views

## Abstract Lung cancer is still the leading cause of death from cancer worldwide primarily because of the fact that most lung cancers are diagnosed at advanced stages. Overexpression of the high mobility group protein HMGA2 has been observed in a variety of malignant tumors and often correlates wi

Increased expression of the LGALS3 (Gale

Increased expression of the LGALS3 (Galectin 3) gene in human non–small-cell lung cancer

✍ Akinobu Yoshimura; Akihiko Gemma; Yoko Hosoya; Eriko Komaki; Yukio Hosomi; Tetsu 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

## Abstract Patients with lung cancer have a poor prognosis because of the high metastatic potential of the neoplasm. Therefore, identifying new molecular targets for anti‐metastatic therapy is very important. To identify novel key factors of tumor metastasis in lung cancer, we established the gene

Correlation between encoded protein over

Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer

✍ Haruhiko Nakamura; Hisashi Saji; Akihiko Ogata; Makoto Hosaka; Masaru Hagiwara; 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 305 KB 👁 1 views

## Abstract The __HER2__ oncogene, which encodes the tyrosine kinase receptor, is commonly overexpressed in several types of cancer. Treatment using a humanized monoclonal antibody bound to __HER2__ product is becoming standard therapy for advanced breast cancer. Overexpression occurs in approximat